Calliditas Has Submitted A Supplemental Application Seeking Full Approval Of Tarpeyo (Budesonide) For The Entire Population From Phase 3 Neflgard Study; Tarpeyo Currently Has Accelerated Approval To Reduce Proteinuria In IgA Nephropathy Patients
Portfolio Pulse from Benzinga Newsdesk
Calliditas has submitted a supplemental application for full approval of Tarpeyo (Budesonide) for the entire population from the Phase 3 Neflgard study. Tarpeyo currently has accelerated approval to reduce proteinuria in IgA nephropathy patients.
June 21, 2023 | 8:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calliditas is seeking full approval for Tarpeyo, which could expand its market and increase revenues.
Calliditas is seeking full approval for Tarpeyo, which is currently approved for a limited population. If granted, this approval would expand the market for Tarpeyo, potentially leading to increased revenues for Calliditas and a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100